<SEC-DOCUMENT>0001104659-18-037806.txt : 20180604
<SEC-HEADER>0001104659-18-037806.hdr.sgml : 20180604
<ACCEPTANCE-DATETIME>20180604073854
ACCESSION NUMBER:		0001104659-18-037806
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20180602
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180604
DATE AS OF CHANGE:		20180604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		18876883

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a18-14776_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report:<b> June&nbsp;4, 2018</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Date of earliest event reported:<b> June&nbsp;2, 2018)</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File   Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">60 Jubilee Avenue, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RX</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (</font>&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-ba.htm',USER='C902552',CD='Jun  2 01:47 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Other Events</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;2, 2018, Adaptimmune Therapeutics plc (the &#147;Company&#148; or &#147;Adaptimmune&#148;) issued a press release announcing an oral presentation on initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). The data were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago,&nbsp;Illinois. During an oral presentation on June&nbsp;2, 2018, entitled, &#147;Pilot Study of NY-ESO-1</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">c259</font>T Cells in Advanced Myxoid/Round Cell Liposarcoma,&#148; Dr.&nbsp;Sandra P. D&#146;Angelo of the Memorial Sloan Kettering Cancer Center presented an update from this ongoing study.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;4, 2018, Company issued a press release announcing a presentation on safety data from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and the triple tumor study in bladder, melanoma, and head&nbsp;&amp; neck cancers. The data were presented during a poster session at the 2018 ASCO annual meeting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;4, 2018, the Company also issued a press release announcing that the independent safety review committee has recommended dose escalation in the Company&#146;s MAGE-A4 basket study, based on an acceptable safety profile in three patients dosed with 100 million cells. The Company will start treating patients with the target dose of one billion transduced MAGE-A4 SPEAR T-cells in its ongoing basket study.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, after confirming expression levels for MAGE-A4 from synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) tumor samples, Adaptimmune has amended the study to add these two indications to the ongoing basket study, which already includes bladder, melanoma, head&nbsp;&amp; neck, esophageal, gastric, ovarian, and non-small cell lung (NSCLC) cancers. Screening of patients with synovial sarcoma and MRCLS is ongoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the same press releases, the Company also provided call in details and the webcast link for a live teleconference that it will host on June&nbsp;4, 2018 at 8:00 AM EDT (1:00 PM BST) to discuss the updated data. Call in details and the webcast link are also available in the Investors section of Adaptimmune&#146;s website (https://www.adaptimmune.com). The press releases are attached as Exhibits 99.1, 99.2 and 99.3 and are incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information contained in Item 8.01 of this Form&nbsp;8-K, including Exhibits 99.1, 99.2 and 99.3 furnished herewith, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="90%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a18-14776_1ex99d1.htm#Exhibit99_1_012357" title="Click to goto ">Press   release dated June&nbsp;2, 2018.</a></font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a18-14776_1ex99d2.htm#Exhibit99_2_013524" title="Click to goto ">Press   release regarding MAGE-A10 pilot studies dated June&nbsp;4, 2018.</a></font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.3</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a18-14776_1ex99d3.htm#Exhibit99_3_014410" title="Click to goto ">Press   release regarding MAGE-A4 basket study dated June&nbsp;4, 2018.</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_012045_3680"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-ba.htm',USER='C902552',CD='Jun  2 01:47 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: June&nbsp;4, 2018</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_012143_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-ba.htm',USER='C902552',CD='Jun  2 01:47 2018' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a18-14776_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibit99_1_012357"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="343" height="77" src="g147761mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit:Risk Profile</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, U.K., June&nbsp;02, 2018 &#151;</font> Adaptimmune Therapeutics plc&nbsp;(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). With eight patients treated, the best overall responses include three confirmed partial responses, one unconfirmed partial response, three stable disease, and one recently treated patient awaiting assessment. These data were presented during an oral presentation by Dr.&nbsp;Sandra P. D&#146;Angelo of the&nbsp;Memorial Sloan Kettering Cancer Center at the American Society of Clinical Oncology (ASCO) annual meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GlaxoSmithKline plc&nbsp;(LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize the NY-ESO SPEAR T-cell therapy program in&nbsp;September&nbsp;2017. Transition of this program to GSK is ongoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We continue to see responses in patients with advanced MRCLS who have failed previous standard chemotherapy,&#148; said Rafael Amado, Adaptimmune&#146;s Chief Medical Officer. &#147;We observe significant proliferation of our SPEAR T-cells in peripheral blood, and infiltration into metastases that were previously devoid of inflammatory cells. These findings bode well for a broad therapeutic potential of SPEAR T-cells across multiple solid tumors.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Data Update from the Ongoing NY-ESO MRCLS Study</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During an oral presentation on&nbsp;June&nbsp;2</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">nd</font>&nbsp;entitled, &#147;Pilot Study of NY-ESO-1<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">c259</font>T Cells in Advanced Myxoid/Round Cell Liposarcoma,&#148; Dr.&nbsp; D&#146;Angelo presented an update from this ongoing study (data cut-off May&nbsp;23 2018).</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Responses:</b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Best overall responses include 3 confirmed partial responses, 1 unconfirmed partial response, 3&nbsp;patients with stable disease, and 1 recently treated patient awaiting assessment</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There is an overall trend in tumor burden decrease among the majority of patients</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The tumor burden decrease across target lesions ranged from 16.9% to 50%</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Three patients have now progressed</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Safety:</b> Thus far, data indicate that NY-ESO SPEAR T-cells remain generally well tolerated in this patient population:</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There was one event of cytokine release syndrome (CRS) <u>&gt;</u> Grade 3, which was characterized by fever, hypotension, rash, headache, and supraventricular tachycardia. The patient was treated with tociluzumab. The CRS resolved six days post-infusion.</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There were four SAEs reported by three patients:</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Grade 3 CRS (noted above), which resolved</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Two Grade 2 events of CRS, both of which resolved</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Grade 2 pleural effusion, which improved with treatment and the patient was subsequently discharged from hospital</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or cancer immunotherapies</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>SPEAR T-cell persistence: </b>Although data are preliminary, there appears to be a correlative trend between SPEAR T-cell persistence and response.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview of Study Design</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Open-label, non-randomized pilot study evaluating the safety, tolerability, and antitumor activity of NY-ESO SPEAR T-cells in patients with MRCLS</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Initially, 10 patients are planned to be enrolled, with potential to enroll an additional 5&nbsp;patients. Patients who do not receive the minimum cell dose or who do not receive the T-cell infusion may be replaced</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_012742_3067"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-mm.htm',USER='C902552',CD='Jun  2 01:56 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Patients must be: <u>&gt;</u> 18 years old; HLA-A*02:01, *02:05, or *02:06 positive; have advanced (metastatic or inoperable) MRCLS expressing NY-ESO-1 at 2+/3+ intensity in <u>&gt;</u>30% of tumor cells by immunohistochemistry (IHC); measurable disease; prior systemic anthracycline therapy; have ECOG status 0 or 1; and adequate organ function</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Lymphodepletion regimen: fludarabine (30mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day) and cyclophosphamide (600&nbsp;mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day) for 3 days; same as Cohort 4 in Synovial Sarcoma study</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Target dose of 1 &#151; 8 &#215; 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>&nbsp;transduced SPEAR T-cells</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Efficacy assessed by overall response rate, time to response, duration of response, progression-free survival, and overall survival at weeks 4, 8, and 12, month 6, and then every 3 months until confirmation of disease progression</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This study is open and actively enrolling</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">More about Soft Tissue Sarcomas</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">MRCLS and synovial sarcoma are both considered soft tissue sarcomas. MRCLS is a type of liposarcoma, characterized by the proliferation of adipocyte (fat cell) precursors called lipoblasts that have stopped differentiating. This malignancy arises from a translocation between chromosomes 12 and 16 resulting in a fusion protein that blocks adipocyte differentiation and promotes malignant transformation. Synovial sarcoma is characterized by a different chromosomal translocation involving the X chromosome and chromosome 18 and, unlike the known immature fat cell cellular origin of MRCLS, the cell of origin for synovial sarcoma remains unknown.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is estimated that there are approximately 2000 patients in the United States and Europe with MRCLS each year. MRCLS has a peak incidence of occurrence in patients who are 30 to 50 years of age and it typically follows a more aggressive course than other liposarcomas. MRCLS also exhibits a unique presentation pattern arising first in the proximal areas of the extremities and typically spreading to the bones (particularly the spine), serosal surfaces, retroperitoneum, abdomen, pelvis, as well as to other soft tissues. This metastatic pattern is different from the characteristic pulmonary spread exhibited by synovial sarcoma.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conference Call Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will host a live teleconference and webcast to answer questions about the updated safety data on June&nbsp;4, 2018 at 8:00 a.m.&nbsp;EDT (1:00 p.m.&nbsp;BST). The live webcast of the conference call will be available via the events page&nbsp;of Adaptimmune&#146;s corporate website at https://bit.ly/2shwniM. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial please dial +1-(833) 652-5917 (U.S.) or +1-(430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (9199456).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About</font></b><b> Adaptimmune</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company&#146;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications.&nbsp;GlaxoSmithKline plc&nbsp;(LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune&#146;s NY-ESO SPEAR T-cell therapy program in&nbsp;September&nbsp;2017. Transition of this program to GSK is ongoing.&nbsp;The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_012920_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-mm.htm',USER='C902552',CD='Jun  2 01:56 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report filed on form 10-Q with the Securities and Exchange Commission (SEC) on May&nbsp;9, 2018 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">S&#233;bastien Desprez &#151; VP, Communications and Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 1235 430 583</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +44 7718 453 176</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sebastien.Desprez@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D. &#151; Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +1 215 825 9310</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +1 215 460 8920</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli.Miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_012952_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-mm.htm',USER='C902552',CD='Jun  2 01:56 2018' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a18-14776_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.2<a name="Exhibit99_2_013524"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="343" height="77" src="g147761moi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- Dosing continues with the one billion &#147;target&#148; cell dose -</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, U.K., June&nbsp;04, 2018 &#151;</font> Adaptimmune Therapeutics plc&nbsp;(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer (NSCLC) and the triple tumor study in bladder, melanoma, and head&nbsp;&amp; neck cancers at the American Society of Clinical Oncology (ASCO) annual meeting.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Based on these safety data, we are enrolling patients and dosing at the target dose of one billion transduced cells in both MAGE-A10 studies, and we anticipate response data later this year,&#148; said Rafael Amado, Adaptimmune&#146;s Chief Medical Officer. &#147;Given our preclinical validation and safety testing data, as well as available clinical results, we anticipate that MAGE-A10 SPEAR T-cells will continue to have an acceptable safety profile as we dose patients in higher cell dose cohorts.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Safety Update</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A safety update from the two ongoing MAGE-A10 pilot studies was presented during a poster session (data cut-off 04 May&nbsp;2018):</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Eight patients in the 100 million cell safety cohorts received MAGE-A10 SPEAR T-cells in the two ongoing pilot studies: 3 in Cohort 1 of the triple tumor study, and 5 in Cohort 1a of the NSCLC study</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Out of the eight patients treated in the safety cohorts, seven received 100 million transduced SPEAR T-cells, and one patient in the triple tumor study received 90 million cells</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There were no deaths attributable to SPEAR T-cell therapy</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To date, there has been no evidence of off-target toxicity</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>There were two events of cytokine release syndrome (CRS), both in the NSCLC study: one Grade 4 and one Grade 1; both events resolved</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Grade 4 event of CRS was considered a dose limiting toxicity (DLT), at the time, and cohort 1a of the NSCLC study was expanded from 3 to 6 patients</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Overall, most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>While no anti-tumor effects were observed at the 100 million cell dose level, transduced SPEAR T-cells cells were detectable in peripheral blood</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Although cells were readily detectable, observed SPEAR T-cell peak expansion was approximately tenfold lower than what was seen at doses of at least one billion cells in other studies, such as those with NY-ESO SPEAR T-cells</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After review of these initial safety data by the safety review committee (SRC), the decision was made to escalate to the next dose of one billion transduced MAGE-A10 SPEAR T-cells in the triple tumor and the NSCLC study. One billion cells was the therapeutic threshold dose observed with SPEAR&nbsp;T-cells targeting NY-ESO in the synovial sarcoma pilot study.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Response data from these ongoing studies is anticipated throughout the remainder of 2018.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview of Study Designs</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Open-label studies of MAGE-A10 SPEAR T-cells in patients with NSCLC; bladder, melanoma, or head&nbsp;&amp; neck cancers (known as &#145;the triple tumor study)</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Patients are screened under a separate protocol (Screening Protocol: NCT02636855) to identify those who have the relevant HLA-A*02 alleles and MAGE-A10 tumor expression</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Both trials are first-in-human studies utilizing a modified 3+3 design with escalating doses of 0.1, 1.0 and 1-6 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>&nbsp;transduced SPEAR T-cells to evaluate safety, including DLTs</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_013916_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\jms\C902519\18-14776-1\task8926809\14776-1-mo.htm',USER='C902519',CD='Jun  2 02:23 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>After completing Group 3 (1-6 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>&nbsp;transduced cells), doses up to 10 billion (1.0 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">10</font>) transduced cells will be included</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The DLT observation period was the first 30 days following SPEAR T-cell infusion for each patient in the initial safety cohorts (100 million cells) and is 7 days in subsequent (<u>&gt;</u>1 billion cells) cohorts</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">NSCLC Study:</i></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Patients must be at least 18 years of age and have Stage IIIb or IV NSCLC, have failed at least one platinum-containing regimen (may have received CPIs), have measurable disease, ECOG 0-1, adequate organ function, and be without brain metastases, history of severe autoimmune disease or current uncontrolled illness</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The lymphodepletion regimen for patients receiving:</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>100 million transduced cells was cyclophosphamide alone (1800 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day) for 2 days</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>One billion (1.0 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>) transduced cells is cyclophosphamide 600mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day and fludarabine 30 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6 and -5</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>One to six billion (1-6 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>) or up to ten billion (1.0 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">10</font>) transduced cells is cyclophosphamide 600mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6, -5 and fludarabine 30 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6, -5, and -4</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Efficacy is assessed by response rate, duration of response, progression-free survival, and overall survival at weeks 4, 8, and 12, month 6, and then every 3 months (for 2 years) and then every 6 months until confirmation of disease progression</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><i style="font-weight:bold;">Triple Tumor Study:</i></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Patients must be at least 18 years of age and have inoperable or metastatic (advanced) urothelial &#147;bladder&#148; cancer, melanoma, or squamous cell head and neck tumors; and, have received standard of care therapies and have progressive disease</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The lymphodepletion regimen for patients receiving:</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>100 million transduced cells was cyclophosphamide 600mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day and fludarabine 30 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6 and -5</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>One billion (1.0 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>) transduced cells is cyclophosphamide 600mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day and fludarabine 30 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6 and -5</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>One to six billion (1-6 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">9</font>) or up to ten billion (1.0 x 10<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">10</font>) transduced cells is cyclophosphamide 600mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6, -5 and fludarabine 30 mg/m<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">2</font>/day on Days -7, -6, -5, and -4</p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Efficacy is assessed by overall response rate, best overall response, time to response, duration of response, duration of stable disease, progression-free survival, and overall survival at weeks 6, 12, 18, and 24 weeks, and then every 3 months until confirmation of disease progression</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conference Call Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will host a live teleconference to answer questions about the updated safety data today, June&nbsp;4, 2018, at 8:00 a.m.&nbsp;EDT (1:00 p.m.&nbsp;BST). The live webcast of the conference call will be available via the events page&nbsp;of Adaptimmune&#146;s corporate website at https://bit.ly/2shwniM. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial please dial +1-(833) 652-5917 (U.S.) or +1-(430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (9199456).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About</font></b><b> Adaptimmune</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company&#146;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications.&nbsp;GlaxoSmithKline plc&nbsp;(LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune&#146;s NY-ESO SPEAR T-cell therapy program in&nbsp;September&nbsp;2017. Transition of this program to GSK is ongoing.&nbsp;The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_013920_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\C902519\18-14776-1\task8926809\14776-1-mo.htm',USER='C902519',CD='Jun  2 02:23 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report filed on form 10-Q with the Securities and Exchange Commission (SEC) on May&nbsp;9, 2018 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">S&#233;bastien Desprez &#151; VP, Communications and Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 1235 430 583</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +44 7718 453 176</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sebastien.Desprez@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D. &#151; Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +1 215 825 9310</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +1 215 460 8920</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli.Miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_013939_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\C902519\18-14776-1\task8926809\14776-1-mo.htm',USER='C902519',CD='Jun  2 02:23 2018' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>a18-14776_1ex99d3.htm
<DESCRIPTION>EX-99.3
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.3<a name="Exhibit99_3_014410"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="343" height="77" src="g147761mqi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">- Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study -</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, U.K., June&nbsp;04, 2018 &#151;</font> Adaptimmune Therapeutics plc&nbsp;(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the independent safety review committee has recommended dose escalation in the MAGE-A4 basket study, based on an acceptable safety profile in three patients dosed with 100 million cells. The company will start treating patients with the target dose of one billion transduced MAGE-A4 SPEAR T-cells in the ongoing basket study.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, after</font> confirming expression levels for MAGE-A4 from synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) tumor samples, Adaptimmune has amended the study to add these two indications to the ongoing basket study, which already includes bladder, melanoma, head&nbsp;&amp; neck, esophageal, gastric, ovarian, and non-small cell lung (NSCLC) cancers. Screening of patients with synovial sarcoma and MRCLS is ongoing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Today&#146;s announcement that we are dosing patients with one billion cells, which we believe is a potentially therapeutic dose based on data from NY-ESO, means that we are on target to get response data in our MAGE-A4 study, to which we have added two solid tumor indications, in 2018,&#148; said James Noble, Adaptimmune&#146;s Chief Executive Officer. &#147;This follows the earlier announcement that pilot studies in our other program, MAGE-A10, have also moved to the one billion cells dose.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Target validation, investigating antigen expression in tumor samples, has been a key focus for Adaptimmune to understand the breadth of patients that have the potential to benefit from SPEAR</font>&nbsp;T-cell treatment. Data from monitoring target antigen expression levels across literature, databases, and tumor samples indicate that MAGE-A4 is expressed in both synovial sarcoma and MRCLS. Evaluation of expression of target antigens, including MAGE-A4, in other cancers will continue.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The MAGE-A4 basket study is a Phase 1, open-label, pilot study to evaluate the safety and efficacy of Adaptimmune&#146;s SPEAR T-cells targeting MAGE-A4 in cancers in which MAGE-A4 is expressed.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Conference Call Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company will host a live teleconference to answer questions about the updated safety data today, June&nbsp;4, 2018, at 8:00 a.m.&nbsp;EDT (1:00 p.m.&nbsp;BST). The live webcast of the conference call will be available via the events page&nbsp;of Adaptimmune&#146;s corporate website at https://bit.ly/2shwniM. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial please dial +1-(833) 652-5917 (U.S.) or +1-(430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (9199456).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About</font></b><b> Adaptimmune</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company&#146;s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications.&nbsp;GlaxoSmithKline plc&nbsp;(LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune&#146;s NY-ESO SPEAR T-cell therapy program in&nbsp;September&nbsp;2017. Transition of this program to GSK is ongoing.&nbsp;The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="PB_1_014417_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-mq.htm',USER='C902552',CD='Jun  2 01:58 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report filed on form 10-Q with the Securities and Exchange Commission (SEC) on May&nbsp;9, 2018 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Media Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">S&#233;bastien Desprez &#151; VP, Communications and Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 1235 430 583</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +44 7718 453 176</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sebastien.Desprez@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investor Relations:</font></b></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D. &#151; Director,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +1 215 825 9310</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">M: +1 215 460 8920</font></p>
<p style="margin:0in 0in .0001pt 5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli.Miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_014432_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C902552\18-14776-1\task8926640\14776-1-mq.htm',USER='C902552',CD='Jun  2 01:58 2018' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g147761mqi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g147761mqi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !- 5<# 2(  A$! Q$!_\0
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M\'>)@ Q(C;(/_/1#4GBC3V\/>(P]H2B$B:(C^$YZ?G6YX[C34=#T[5XT W
M^N&&0/PYK9<JDK?#(AWMYHZ#Q#XBCTWPRVH0D%I4 B^IKSWP7X>/B+5I+R_R
MUM"=\A;^-NN/\:HZSJSW.A:=8[\B$L2OISQ^E=7/(/#GPOC$68[B] 7<.I+=
M?_'17DU8VJ.+V1]#A4Z>%CR?%4=C,\6>,I]1N&TW2&*6BG9F/K)_]:M'P=X1
MU'2[R+5+RY6U3^*-CRP]#5/X=Z5 L=WK=ZN8[8$)GU R3_*LK4=6U;QGK/V>
MUWE&.(X5. !ZG_Z]9W^TSI</BP]*RBOB;/958.H92"#T(IU9/AJSN]/T&VM;
M_;YT0*DJ<\9XK6K=;'STXJ,FD[F+XFUX:#IPF55>9VVHAZ&G>&];&O:4+DJJ
M2JQ61%/0_P#ZJY^8?\)/XW6+A[.P&6YX)_\ UTFG'_A&O',UDWRVE^-T?' ;
MM^N1^(KJ]E'DY?M;F7,[WZ'<T4F<<UR>I>,W^W/8Z+:/>SKPS+DJ#^'6L80E
M-Z%-I'6US6C:U=WOBC4[*9U,%NQ$8"@$<^M5$\5:KIKJ==TIXH&/,T?(7ZU!
MX5F2?QGK$L+!XW)96!R",FM52<8R;[$N5VCMJ6N6U#Q1J":A-9Z=H\\[1G:9
M#G;G\*J/XQU3374ZQH[Q0L<>8N<#^GZU"H38^9':45C:IX@CL] &J6R">-@"
MH)VY!K+E\://%#%IEB]U>R)N>-.5C^II1I3EJD-R2.MIK':I/H*XQ_%VL:5(
MIUK22D+$#S(^@_I^M;5_KC'1%OM*MFOA)P$3.0._0'I3=*2MYBYD3Z+KD.M?
M:?)C=/(?8V[N>?\ "I=:OY--TN:ZA@,[H.$'>N \,:WJ.G_;?LFD37?FR[GV
M;OD//' /K76/XCNX/#<VIW>FM!+&VWR)"1D9ZY(_I5U*+C/1:>HE*Z-?2[M[
M[3H;B6(PO(H8H>U6ZYB]\6M9Z!8ZE]E5C<D H9,!?QQ5>7Q7J6H,PT+3&GC3
M[TS_ '2>X'K4^QD];60^9'7T5R&E^.4:66VUFW-E/&I8[N,^V#R#4;>*=;OE
M:;2M'9K8='?.7'L/\,T>PG?4.='9T5SGASQ6FM3R6EQ";:\C&2A[XZ_C[5'?
M^,H].UNYL;B#"0H&5U;+.Q PH&/>I]E/FY;:AS*USIZ*XJX\4>((D^U_V*RV
MG7#9W8]_3\JM?\)Y9OI<4T$3RW<K;%M5Y;=_A5>PGT#G1U=%<3<>*?$&G@7%
M]H^VU/)QG*CW/;\:WH_$$-SX>EU2U7>L<98H3CD=C4RI2B"DF;%%9F@:L=:T
MF.\:(1%R1M#9Q@^M6=1NS8Z?/<A-YB0MMSC-0XM2Y>H[Z7+5%<VGBMW\*/K'
MV50RMCRM_'7'7%4U\9W-_#%'I.FO<73*#)@DI$3T!./\*T5&;Z"YD=A17%1^
M,[_3KQ(->TXP(YP)%S@?XUU5WJ5M9:>U[-*! %W;O7TQ4RIRC:_4:DF6Z*XZ
M+Q-KFK[I=&TG-L,XDF;&[Z9P/RS5O1_%OVJ__L_4[5K*\[!NC&J=&:0N9'34
M4@HK(HCGGBMXR\TB1J!DECBN)3Q5IEWK@@@T.WFD>7:LY"Y;_:^[G]:U/&NA
M76M6ML++!DC<Y!; (/\ ^JL_3-%L?!MNVH:G.CW6WY5';V%=-*,%&[U;Z$2;
MN6O%GB&PTJ]BANM+AO9"F[+[<J/Q!JQJ>LV=IX4M+V;3HI(90FRV.-JY&1VQ
MQ]*X6)+GQAXGR00)6^;'\""M?XAZC&UQ;:9!@);KE@.@)Z#\!_.MO8I.,.O4
MCF=FR&?QGI,2H[^%;4J^=I.SG'_ *Z/7M=LK3PQ8W\NE0WEO*5"PMMVQ94],
M@CC&.E<EXE\/R6G@_3;K:=Z$^8/0-S6KX;9/%'@2YT=F47, PGY[E/Y\5YU5
M_O))?(]NE2I_5Z=9]'[VK-G0M<L]4\,W=Q::5%&D)8/:+MPW&>PQS]*S/#7C
M+1[G5/(&E6^F.XP)5VC)]"0HQ7+>$]>?POK$MO>HRP2'9,I'*D=ZW=<\!)JC
MG4/#\\3I+\WE[N,^QK)2DTFC>>&HTYRA4TC+9W?X_P#!/1E97&58,/4&LSQ)
MJJZ1HL]QG$A&V/\ WC1X:TV32=!M;68_OE4F0YSR3FN<\0$^(O%EMI$>3;V_
MS38/Y_T%==&/-*[V6YXE5*+:B[CO!VHZ3I>E%[F^B%U<-ODSG(]JB\:ZAIFI
M:?#<65]&;RUD#)M)R0>N/T/X5O\ _"&Z)_SY)1_PANB?\^25M[2GS\^MS+E=
MK%:XUUKOP-+J$)Q*8<-_LMT-'@73X[70(YP 9;@EV;OCL*P-+MC:7VJ>&KAL
M)."83ZGJ/S&*M^$]?CT=7TC5B8)(G.QGZ?2JG"T)*'K\@3U5SMIH8[B)XI4#
MQN,,K#((KA_!UHFG>*M6ME;*1?*"?3)KH=3\4Z=I\!*SK-,P_=Q1G)8]JY3P
MM]JFU;6_M (NGB;<.^XYJ*49*G*^PY-71OW7C2/[6UKI=E-?RH<,4.%'XXJG
MJ?B&[N-,N8-0T"XCBDC(W*V\ XX)&.QJ+P'J%E:6<UG<,D-X)"7W\%A6OXB\
M0V=KIT\,4JS7,L;*D:')Y'4^U-Q49\JB*]U>YRL+$_#.4$DA9L#/;FNL\':=
M'8>'X"BCS)AO=AU-<E!_R32?/7S_ .M:_A/Q)#::?#I^IMY#J,Q._P!UU/O6
ME6+<9<O<46DU<ZZ[M8KRUDMYT#QR+M8$5Q_@1W@;4[$L6CA8E?;M6QK7BRPT
MRT<QSI-<$?)&AR<U2\$:5/;:?<7ETI6:[)8*>N*QBG&E+FZE/62L1?#_ /YB
MW_7Q_C6CXX_Y%2[_ . _S%8?@W4[73[[5+6\E6&1IMR[^,X)_P :UO%MY!>^
M$+N6VE66,,%W*>,@BKDG[=/S0D_=.=UE=W@31E/0L!7>Z;;QVNFVT,2A42,
M ?2N#U?_ )$;1/\ >6O0;;_CUA_W%_E4U_A7JQQW.(\=64,NO:4649F8(Y'<
M;A_C7=1QK%&L: !5& !7'>-O^0]HG_77_P!F%=G4U'^[@$=V<3?1K;_%"Q:(
M!3+'E\=_E84U+2*[^*$_G+N$48D4>X5?\:DU3_DIVF_]<OZ/4EG_ ,E0O?\
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2O48HL@=6;DY-ZL!12T4R#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g147761moi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g147761moi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !- 5<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BD-4;F[
M2X\ZSM+V**\ XSABOX4TK@7@RDD C(ZBEKR348==\,:M]KEFD,CM_KP2RR>Q
M_P #7?\ AGQ+#K]IDXCND'[R,?S'M6U2@XQYD[HA3N[&Y245Q'C7QQ_91;3]
M,8&[(^>3J(OI[USRDHJ[.FA0G7GR01VP=22 P)'49Z4M>5>#=&U^[OAJB7<E
MM$YW/+*2QF_ ]1[FO2[74+6ZE>&"YAFEC^^$8'%*,KFF)PRHRY8RYN]NA;HH
MHJCE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH BG=4B.9%C)& Q/0UYCKWA;5-,
MF?4$F-PI8N98_O#W-=7XWTG4-7LX$L%#"(EW7=@GTQ^M<WX2\1W-KJ TS42T
MD$A\O$G)0_X5V4$XQ<XN_=&<[-V9H>'/$$7B*W;1]: D=UPCGJW_ ->N<D2Y
M\'>)@ Q(C;(/_/1#4GBC3V\/>(P]H2B$B:(C^$YZ?G6YX[C34=#T[5XT W
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M$+N6VE66,,%W*>,@BKDG[=/S0D_=.=UE=W@31E/0L!7>Z;;QVNFVT,2A42,
M ?2N#U?_ )$;1/\ >6O0;;_CUA_W%_E4U_A7JQQW.(\=64,NO:4649F8(Y'<
M;A_C7=1QK%&L: !5& !7'>-O^0]HG_77_P!F%=G4U'^[@$=V<3?1K;_%"Q:(
M!3+'E\=_E84U+2*[^*$_G+N$48D4>X5?\:DU3_DIVF_]<OZ/4EG_ ,E0O?\
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2O48HL@=6;DY-ZL!12T4R#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g147761mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g147761mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !- 5<# 2(  A$! Q$!_\0
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M\'>)@ Q(C;(/_/1#4GBC3V\/>(P]H2B$B:(C^$YZ?G6YX[C34=#T[5XT W
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M$+N6VE66,,%W*>,@BKDG[=/S0D_=.=UE=W@31E/0L!7>Z;;QVNFVT,2A42,
M ?2N#U?_ )$;1/\ >6O0;;_CUA_W%_E4U_A7JQQW.(\=64,NO:4649F8(Y'<
M;A_C7=1QK%&L: !5& !7'>-O^0]HG_77_P!F%=G4U'^[@$=V<3?1K;_%"Q:(
M!3+'E\=_E84U+2*[^*$_G+N$48D4>X5?\:DU3_DIVF_]<OZ/4EG_ ,E0O?\
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2O48HL@=6;DY-ZL!12T4R#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
